Trial Profile
Phase II study of antineoplastons A10 and AS2-1 in patients with bronchial alveolar carcinoma of the lung
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Antineoplaston A10/antineoplaston AS2-1 (Primary)
- Indications Lung cancer
- Focus Therapeutic Use
- 30 Jan 2018 Status changed from active, no longer recruiting to discontinued due to slow accrual.
- 04 Sep 2005 New trial record.